Immediate and pre-emptive therapies for SARS CoV-2 positive and negative patients with high risk for Covid-19 pneumonia: Immunocompromised Collaborative Host Swiss Cohorts Based Trial Platform Initiative
Research Project | 01.07.2020 - 28.02.2023
|
01.07.2020
- 28.02.2023
This multicenter randomized controlled trial embedded in the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study provides crucial information about the efficacy and safety of the mRNA SARS-CoV-2 vaccines.
Follow this link for more information
Publications
Amstutz, Alain et al. (2024) ‘Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study’, Journal of Infectious Diseases, 230, pp. e847–e859. Available at: https://doi.org/10.1093/infdis/jiae291.
Amstutz, Alain et al. (2024) ‘Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study’, Journal of Infectious Diseases, 230, pp. e847–e859. Available at: https://doi.org/10.1093/infdis/jiae291.
Chammartin, Frédérique et al. (2024) ‘Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1’, AIDS, 38, pp. 217–222. Available at: https://doi.org/10.1097/qad.0000000000003751.
Chammartin, Frédérique et al. (2024) ‘Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1’, AIDS, 38, pp. 217–222. Available at: https://doi.org/10.1097/qad.0000000000003751.
Griessbach, Alexandra et al. (2023) ‘Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)’, Open Forum Infectious Diseases, 10. Available at: https://doi.org/10.1093/ofid/ofad150.
Griessbach, Alexandra et al. (2023) ‘Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)’, Open Forum Infectious Diseases, 10. Available at: https://doi.org/10.1093/ofid/ofad150.
Chammartin F et al. (2022) ‘Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.’, AIDS (London, England), 36(10), pp. 1465–1468. Available at: https://doi.org/10.1097/qad.0000000000003246.
Chammartin F et al. (2022) ‘Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.’, AIDS (London, England), 36(10), pp. 1465–1468. Available at: https://doi.org/10.1097/qad.0000000000003246.
Speich, Benjamin et al. (2022) ‘Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial’, Clinical Infectious Diseases, 75, pp. E585–E593. Available at: https://doi.org/10.1093/cid/ciac169.
Speich, Benjamin et al. (2022) ‘Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial’, Clinical Infectious Diseases, 75, pp. E585–E593. Available at: https://doi.org/10.1093/cid/ciac169.
Speich B et al. (2021) ‘A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.’, Trials, 22(1), p. 724. Available at: https://doi.org/10.1186/s13063-021-05664-0.
Speich B et al. (2021) ‘A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.’, Trials, 22(1), p. 724. Available at: https://doi.org/10.1186/s13063-021-05664-0.
Members (1)
